argenx's $2.2B Forte Biosciences Deal: FB102 Anti-CD122 & Vyvgart Synergy

On July 27, 2026, argenx (Euronext & Nasdaq: ARGX) agreed to acquire Forte Biosciences (Nasdaq: FBRX) for $77.00 per share in cash, a total equity value of approximately $2.2 billion, via a front-end cash tender offer followed by a second-step merger. The price represents an ~86% premium to Forte's volume-weighted average price (VWAP) since it reported positive Phase 1b vitiligo data on July 9, 2026, and roughly a 41% premium to the prior closing price. The deal is funded entirely from argenx cash on hand — no financing condition — and is expected to close in Q3 2026. The prize is FB102, a first-in-class anti-CD122 (IL-2/IL-15 receptor beta) monoclonal antibody that adds a cell-mediated autoimmune mechanism to argenx's antibody-mediated Vyvgart (efgartigimod access guide) franchise. This deal analysis unpacks the economics, the CD122 biology, the Phase 1b evidence that justified the premium, and what FB102 adds to the Vision 2030 portfolio.

+-----------------------------------------------------------------------------------+
|                        ARGENX DUAL-PILLAR AUTOIMMUNE PLATFORM                      |
+-----------------------------------------------------------------------------------+
|                                                                                   |
|   PILLAR 1: FcRn BLOCKADE (Vyvgart / Efgartigimod) -- EXISTING FRANCHISE           |
|   Mechanism: Accelerates degradation of pathogenic IgG autoantibodies              |
|   Approved indications: Myasthenia Gravis, CIDP, ITP, Pemphigus Vulgaris           |
|                                                                                   |
|   PILLAR 2: CD122 INHIBITION (FB102 / Anti-CD122 mAb) -- ACQUIRED VIA FORTE        |
|   Mechanism: Blocks shared IL-2 / IL-15 signaling on pathogenic T & NK cells       |
|   Lead indications: Vitiligo, Celiac Disease, Alopecia Areata                      |
|                                                                                   |
+-----------------------------------------------------------------------------------+

---

Direct Commercial & Regulatory Answer

Why did argenx pay $2.2 billion — an ~86% premium to Forte's post-data VWAP and ~41% to the last close — for a single Phase 1b antibody? argenx acquired Forte Biosciences to solve a structural gap in its core business: Vyvgart (efgartigimod access guide) is an FcRn inhibitor built for IgG-autoantibody-mediated diseases. It does not address the cell-mediated, T-cell-driven tissue destruction that defines non-segmental vitiligo, alopecia areata, or celiac disease. By acquiring FB102 — a humanized IgG1 monoclonal antibody against CD122 (the shared IL-2/IL-15 receptor beta subunit, IL-2Rβ / IL-15Rβ) — argenx adds a second independent immunology pillar that downregulates pathogenic CD8+ tissue-resident memory T cells ($T_{RM}$) and natural killer (NK) cells while relatively sparing regulatory T cells ($T_{reg}$). The asset arrives with a randomized, placebo-controlled Phase 1b vitiligo readout (29.6% vs 7.9% mean FVASI improvement at week 24), earlier Phase 1b celiac activity, and a Phase 2 celiac readout expected in H2 2026 — giving argenx both near-term catalysts and a "pipeline-in-a-product" thesis spanning dermatology, gastroenterology, and rheumatology.

---

Transaction Architecture & Financial Valuation

Under the definitive merger agreement, argenx will acquire all outstanding Forte shares through a wholly owned subsidiary via a cash tender offer at $77.00 per share in cash, representing approximately $2.2 billion in total equity value. Once the tender completes, the subsidiary merges with Forte and any untendered shares convert into the right to receive the same $77-per-share cash consideration. The transaction is not subject to a financing condition.

Deal Terms At A Glance

                  FUNDING THE $2.2B AGAINST THE argenx BALANCE SHEET
  ┌──────────────────────────────────────────┬────────────────────────────────┐
  │ ~$2.2B all-cash tender at $77/share      │ Funded from cash on hand       │
  │ ~86% premium to post-data VWAP           │ No financing condition         │
  │ ~41% premium to last close               │ argenx held $5.2B in cash,     │
  │                                          │ cash equivalents & current     │
  │                                          │ financial assets (06/30/2026)  │
  └──────────────────────────────────────────┴────────────────────────────────┘

The funding math is the central financial story. argenx reported $5.2 billion in cash, cash equivalents and current financial assets as of June 30, 2026, meaning the ~$2.2B outlay consumes roughly 42% of argenx's liquid balance sheet — a substantial but absorbable bet for a company that generated $1.5 billion in Q2 2026 product net sales (+60% year-over-year, +17% sequentially) and $494M in operating profit (+146%) off the Vyvgart franchise. argenx is spending down a cash fortress, not diluting equity or taking on deal debt, which is why the agreement carries no financing condition and why the all-cash structure was feasible at a ~41% premium to the last close.

---

CD122 Target Biology & Signaling Pathways

CD122 (IL-2Rβ / IL-15Rβ) is the shared beta subunit of both the intermediate-affinity and high-affinity receptor complexes for Interleukin-2 (IL-2) and Interleukin-15 (IL-15). FB102 is designed to block signaling through this shared subunit, which is the mechanistic basis for its differentiated autoimmune profile.

                      INTERMEDIATE-AFFINITY RECEPTOR (CD122 + CD132)
                       Expressed on Effector T Cells & NK Cells
                                       │
                      FB102 Binds CD122 and Blocks IL-2 / IL-15 Binding
                                       │
                  ┌────────────────────┴────────────────────┐
                  ▼                                         ▼
        Inhibits IL-2 Signaling                     Inhibits IL-15 Signaling
        (CD8+ T_RM survival)                        (Cytotoxic NK maintenance)
                  │                                         │
                  └────────────────────┬────────────────────┘
                                       ▼
                       Reduces JAK1/JAK3 -> STAT5 Signaling
                                       │
                  Downstream: lower IFN-gamma, CXCL9, CXCL10 in tissue

Effector Cells vs. Regulatory T Cells: Why CD122 Is Selective

The therapeutic rationale for FB102 rests on how CD122 is used differently across immune cell subsets:

1. Intermediate-affinity complex (CD122/CD132 heterodimer): Expressed on memory CD8+ cytotoxic T cells, tissue-resident memory T cells ($T_{RM}$), and mature NK cells. These effector populations depend on IL-2 and especially IL-15 for survival and maintenance in inflamed tissue. Blocking CD122 starves them of those survival signals.
2. High-affinity complex (CD25/CD122/CD132 heterotrimer): Expressed constitutively on regulatory T cells ($\text{CD4}^+\text{CD25}^+\text{FoxP3}^+\ T_{reg}$). Here CD25 (IL-2Rα) confers very high IL-2 binding affinity and presents IL-2 to CD122, so regulatory T cells can still receive IL-2 survival signaling at therapeutic exposure levels. This is the basis for the selective, Treg-sparing profile attributed to CD122 blockade in Forte's preclinical and early-clinical data.
3. Downstream cascade: By blocking CD122 engagement on pathogenic CD8+ $T_{RM}$ cells, FB102 reduces JAK1/JAK3 trans-phosphorylation and downstream STAT5 signaling, lowering the pro-inflammatory chemokine output (CXCL9, CXCL10, IFN-γ) that recruits further autoreactive T cells into tissue.

Preserving regulatory T-cell function is the pivotal biological differentiator. Non-selective cytokine blockade or broad T-cell depletion can deplete $T_{reg}$ populations alongside effectors; CD122 blockade is designed to avoid that by leaving the CD25-dependent, high-affinity IL-2 survival axis on Tregs intact. argenx and Forte are careful to attribute the selective-depletion, Treg-sparing profile to preclinical and early-clinical evidence rather than established Phase 3 efficacy — FB102 remains an investigational asset.

---

Mechanistic Contrast: FcRn Inhibition (Vyvgart) vs. CD122 Inhibition (FB102)

argenx's portfolio expansion is a move from single-mechanism autoantibody clearance toward dual-pathway autoimmune control.

Comparative Biology: FcRn Blockade vs. CD122 Blockade

Where Vyvgart (efgartigimod access guide) excels at removing circulating pathogenic autoantibodies in generalized myasthenia gravis (MG access landscape), it cannot eliminate autoreactive CD8+ memory T cells that persist locally in skin epidermis or gut mucosa. FB102 addresses that cellular reservoir directly. In diseases like non-segmental vitiligo, melanocyte destruction is executed by CD8+ cytotoxic T cells infiltrating the basal epidermis; clearing circulating antibodies has little impact on those tissue-resident cells. The strategic logic of the deal is that FB102 addresses the exact biological driver of cutaneous and mucosal cell-mediated autoimmune destruction that FcRn blockade cannot reach — making the two mechanisms complementary rather than redundant.

---

Phase 1b Clinical Evidence: What Justified the Premium

Forte reported topline Phase 1b vitiligo data on July 9, 2026 — the readout that reset Forte's share price and established the VWAP baseline against which argenx's 86% premium is measured. The trial is the evidentiary core of the deal.

Phase 1b Vitiligo Trial Design

The study was a double-blind, placebo-controlled Phase 1b in non-segmental vitiligo, enrolling 43 participants randomized 3:1 (32 FB102 : 11 placebo) across two dosing cohorts (Cohort A and Cohort B). The primary endpoint was the mean percentage improvement from baseline in the Facial Vitiligo Area Scoring Index (FVASI) at week 24, following a 12-week treatment period with continued follow-up off-treatment. Efficacy was assessed by central review. Because one placebo subject was excluded from the efficacy-evaluable population due to facial hair (and that subject also experienced vitiligo progression), Forte reported two complementary populations: the protocol-defined efficacy-evaluable (EE) population (32 FB102 / 10 placebo) and the intent-to-treat (ITT) population (32 FB102 / 11 placebo).

Phase 1b Vitiligo Results — FVASI at Week 24

Beyond the mean FVASI improvement, the responder analysis and durability signal are what make this Phase 1b unusually clean for an early-stage dermatology asset:

• Responder rates (week 24): Overall, 34.4% of FB102-treated patients reached FVASI50 and 12.5% reached FVASI75. In the severe-disease subgroup (baseline FVASI ≥ 0.75), response was stronger: 58.8% reached FVASI50 and 23.5% reached FVASI75, while placebo subjects did not reach these thresholds.
• Early and durable separation: Statistically significant separation from placebo emerged by day 64 (p=0.023) and continued through week 24 even though dosing stopped at week 12 — FB102 added a further ~8 percentage points of FVASI improvement between weeks 12 and 24 (and ~14 points in the severe subgroup), indicating a disease-modifying rather than purely symptomatic effect.
• Direction of change: 84% (27/32) of FB102-treated patients improved and 0% (0/32) worsened through week 24, versus 27% (3/11) of placebo patients who worsened — a clinically meaningful asymmetry.
• Safety: All adverse events were mild or moderate, with FB102 comparing favorably to placebo. No severe infections, cytokine release, or systemic immunosuppression signals were reported in this Phase 1b readout.

Phase 1b Celiac Disease — the H2 2026 Catalyst

Before vitiligo, FB102 had reported positive Phase 1b activity in celiac disease (June 23, 2025). That trial enrolled 32 subjects (24 FB102 / 8 placebo, 3:1 randomization) at 9 sites in Australia and New Zealand, giving three doses then a fourth on day 22, overlaid on a 14-day graded oral gluten challenge, with paired duodenal biopsies at baseline and end of challenge. Forte reported positive histological and symptom endpoints for FB102 versus placebo. A Phase 2 celiac disease trial is ongoing, with topline results expected in H2 2026 — the most important near-term clinical catalyst for the acquired asset and a key test of whether the mechanism translates beyond dermatology.

                       PHASE 1b VITILIGO RESPONSE (WEEK 24, EFFICACY-EVALUABLE)
  ┌────────────────────────────────────────────────────────────┬───────────┐
  │ FB102: 29.6% mean FVASI improvement (p=0.020 vs placebo)   │ Placebo   │
  │ Severe-disease subgroup: 43.2% (p=0.006)                    │ 7.9% mean │
  │ FVASI50 34.4% / FVASI75 12.5% overall                       │ (EE n=10) │
  │ 84% improved, 0% worsened; separation by day 64            │           │
  └────────────────────────────────────────────────────────────┴───────────┘

The takeaway for BD and investors: this is a randomized, placebo-controlled, centrally read Phase 1b with a positive primary endpoint, a dose-response across two cohorts, a large severe-disease effect, off-treatment durability, and a clean safety profile — a comparatively strong early data package, but still Phase 1b. The $2.2B is a bet on translating that signal in Phase 2 vitiligo and on the H2 2026 celiac readout.

---

How FB102 Fits the Vyvgart-Led Portfolio and Vision 2030

argenx is not building FB102 in isolation. The Forte acquisition slots a cell-mediated mechanism alongside an existing immunology stack:

• Vyvgart / efgartigimod (FcRn) — the commercial engine: $1.5B in Q2 2026 product net sales, approved across myasthenia gravis (all serotypes), CIDP, ITP (Japan), and pemphigus, with continued label expansion.
• Empasiprubart (anti-C6) and adimanebart — argenx pipeline candidates advancing toward later-stage reads.
• FB102 (anti-CD122, acquired) — the new T-cell/NK-cell mechanism for cell-mediated autoimmune disease.

This maps to argenx's stated Vision 2030 targets: 50,000 patients treated, 10 labeled indications, and five late-stage pipeline candidates. FB102 is the clearest route to adding dermatology and gastroenterology indications to a portfolio currently anchored in neurology and hematology, and its "pipeline-in-a-product" profile — vitiligo, celiac disease, alopecia areata, with type 1 diabetes noted as an exploratory future direction on Forte's pipeline — is what supports paying a Phase 1b premium.

---

Competitive Landscape: Where FB102 Would Compete

If FB102 advances, it would enter indications currently dominated by small-molecule JAK inhibitors, which carry class boxed warnings. A targeted, Treg-sparing biologic with a non-JAK mechanism is the differentiation argument argenx is buying.

FB102's commercial edge, if Phase 2/3 confirm efficacy and safety, is mechanistic: rather than broadly suppressing cytokine cascades downstream (as JAK inhibitors do), it targets the shared IL-2/IL-15 survival axis on the pathogenic cells themselves while sparing regulatory T cells — a profile that could matter for chronic-disease tolerability and for differentiating against JAK-class labeled risks. That is a thesis to be proven, not an established efficacy advantage.

---

Expected Commercial Access & Payer Positioning

FB102 is years from approval, so any access analysis is forward-looking. Still, the expected positioning follows recognizable patterns for specialty immunology biologics and is consistent with how payers manage the existing JAK-inhibitor class in these indications.

                      EXPECTED UTILIZATION-MANAGEMENT FRAMEWORK FOR FB102
  ┌─────────────────────────────────────────────────────────────────────────┐
  │ EXPECTED ROUTING                                                        │
  │ • Subcutaneous biologic -> pharmacy benefit / specialty pharmacy        │
  │   (parallels Vyvgart Hytrulo's SC commercial channel)                   │
  ├─────────────────────────────────────────────────────────────────────────┤
  │ EXPECTED PA GATES (vs established JAK class)                            │
  │ • Severity documentation (e.g., F-VASI / SALT clinical scores)          │
  │ • Step therapy through topical agents and/or oral JAK inhibitors first  │
  │ • Re-authorization tied to objective improvement                        │
  ├─────────────────────────────────────────────────────────────────────────┤
  │ DIFFERENTIATION LEVER                                                   │
  │ • Non-JAK, Treg-sparing profile may support medical-necessity appeals   │
  │   for patients unsuited to JAK-class labeled risks                      │
  └─────────────────────────────────────────────────────────────────────────┘

For vitiligo and alopecia specifically, payers today enforce prior authorization and step therapy against the JAK class — for example, requiring topical corticosteroids/calcineurin inhibitors before systemic therapy, and documented baseline severity scores (F-VASI for vitiligo, SALT for alopecia). A subcutaneous anti-CD122 biologic would plausibly sit behind those same first-line steps and would compete on whether its targeted, non-JAK mechanism justifies a different safety/tolerability profile. For celiac disease — where no drug is approved — the access question is more fundamental: whether any mechanism can demonstrate histological and symptom benefit robust enough to earn coverage against a gluten-free diet as standard of care. FB102's celiac Phase 1b histological signal, and the pending Phase 2 readout, are what will eventually answer that. (Projected pricing is not asserted here; FB102 has no disclosed price and is not approved.) This is the same access-framing logic the site applies across its immunology coverage, including the EULAR 2026 readouts and the broader 2026 biopharma M&A context.

---

Clinical Development & Execution Risks

The strategic case is strong, but argenx is paying a Phase 1b premium and inherits real execution risk:

1. Phase 1b → Phase 2 translation: A positive placebo-controlled Phase 1b FVASI signal is not a guarantee of a positive Phase 2/3 primary endpoint. Vitiligo repigmentation is slow, and responder-based endpoints (FVASI50/75) in larger, longer trials are the real test. Forte's planned Phase 2 vitiligo initiation will be the next data point.
2. The celiac Phase 2 readout (H2 2026) is the decisive catalyst: The $2.2B is arguably a bet on celiac and pipeline breadth as much as on vitiligo. A failed or ambiguous celiac Phase 2 would materially change the asset's risk-reward.
3. Long-term Treg and immune-surveillance safety: Short-term CD122 blockade appears Treg-sparing, but multi-year chronic dosing in autoimmune populations must be monitored for subtle shifts in regulatory function, infection risk, and immune surveillance.
4. Close risk: The tender is conditioned on majority share tender and HSR clearance; while no overlap issues are apparent, regulatory or tender shortfalls could delay the Q3 2026 close.
5. Manufacturing and formulation: FB102 must be scaled into a stable, high-concentration subcutaneous presentation (autoinjector/syringe) suitable for chronic self-administration — a non-trivial process-validation step before any launch.

---

Frequently Asked Questions (FAQ)

What is FB102 and how does its mechanism differ from Vyvgart?

FB102 is a humanized IgG1 monoclonal antibody targeting CD122 (the shared IL-2/IL-15 receptor beta subunit). It is designed to block IL-2 and IL-15 signaling on pathogenic CD8+ memory T cells and NK cells that drive cell-mediated tissue destruction, while relatively sparing regulatory T cells. Vyvgart (efgartigimod), by contrast, targets FcRn to accelerate degradation of circulating IgG autoantibodies in antibody-mediated autoimmune diseases such as myasthenia gravis.

What are the financial terms of argenx's acquisition of Forte Biosciences?

argenx will acquire Forte for $77.00 per share in cash via a tender offer, a total equity value of approximately $2.2 billion. The all-cash deal is funded entirely from cash on hand, represents an ~86% premium to Forte's VWAP since its July 9, 2026 Phase 1b vitiligo data (and ~41% to the prior closing price), and is expected to close in Q3 2026 subject to majority tender and Hart-Scott-Rodino clearance.

What did the FB102 Phase 1b vitiligo trial show?

In a 43-patient, double-blind, placebo-controlled Phase 1b, FB102 achieved a 29.6% mean FVASI improvement from baseline at week 24 versus 7.9% for placebo in the efficacy-evaluable population (p=0.020), with a 43.2% versus 0.5% effect in the severe-disease subgroup (p=0.006). Overall FVASI50/FVASI75 responder rates were 34.4%/12.5%; benefit separated from placebo by day 64 and continued improving through week 24 after the 12-week treatment course ended.

Which indications is argenx prioritizing for FB102?

FB102's lead indications are vitiligo, celiac disease, and alopecia areata, with type 1 diabetes noted as an exploratory future direction. The most important near-term catalyst is the ongoing Phase 2 celiac disease trial, with topline results expected in H2 2026.

Why is argenx paying a Phase 1b premium?

The premium reflects a comparatively clean randomized Phase 1b vitiligo readout (positive primary endpoint, dose-response, large severe-disease effect, off-treatment durability, clean safety), earlier Phase 1b celiac activity, the pending Phase 2 celiac readout, and FB102's "pipeline-in-a-product" breadth — plus the strategic value of adding a second, cell-mediated mechanism alongside the FcRn/Vyvgart franchise and advancing Vision 2030.

---

Sources

1. argenx SE / Forte Biosciences Joint Press Release: argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline. Published July 27, 2026. Available via argenx.
2. argenx SE SEC Form 6-K / Merger Agreement: Filed with the US Securities and Exchange Commission on July 27, 2026 (tender-offer terms, HSR and majority-tender conditions, all-cash funding, Q3 2026 close).
3. Forte Biosciences Press Release (Business Wire): FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period. Published July 9, 2026. Available via Forte Biosciences.
4. Forte Biosciences FB102 Phase 1b Vitiligo Investor Presentation: Published July 9, 2026 (efficacy-evaluable vs ITT populations, Cohort A/B, FVASI50/75 responder and severe-disease subgroup detail, day-64 separation).
5. Forte Biosciences Press Release: Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1b Study. Published June 23, 2025.
6. argenx SE Press Release: argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update ($5.2B cash, cash equivalents and current financial assets; $1.5B Q2 2026 product net sales; Vision 2030 targets). Available via argenx.
7. FDA Drugs@FDA: Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Prescribing Information & Regulatory History. US Food and Drug Administration. Available via FDA.gov.